Shamburg News · 8-K filed Nov 12, 2026, 4:43 PM EST

Spero Therapeutics Reports Third Quarter 2026 Results and Business Update

SPRO · Spero Therapeutics, Inc.

  • Earnings
  • Leadership change
  • Financing
  • Materiality: high

Spero Therapeutics reported a third quarter 2026 net loss of $44.3 million, or $0.76 per diluted share, compared with a net loss of $7.4 million, or $0.13 per share, for the third quarter of 2025. The company reported no revenue for the quarter versus $5.4 million a year earlier, and research and development expenses of $38.2 million, driven by a $35M upfront payment to Innovent. Cash and cash equivalents were $107.9 million as of September 30, 2026, which the company expects to fund operations into the second half of 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458637.

Written from the filing by Shamburg Markets. Figures are as reported by the company.